U.S. Osteoporosis Drugs Market Size, Share & Forecast 2026–2032

ID: MR-11048 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Osteoporosis Drugs
  • ✓Market Size 2024: USD 4.6 billion
  • ✓Market Size 2032: USD 6.4 billion
  • ✓CAGR: 4.2%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Biosimilar denosumab erosion: Sandoz launched denosumab biosimilars in 2025 after settling litigation with Amgen, and Celltrion and Samsung Bioepis are following close behind. Prolia's injectable share will erode faster than Part B spend data currently implies.
FINDING 02
Anabolic agents outgrow generics: The consensus view holds that generic alendronate has commoditized the U.S. osteoporosis market. Yet the real growth is in anabolic agents such as Evenity and Tymlos, where sequential therapy after denosumab discontinuation is becoming standard practice in high-risk patients.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure PBM formulary placement: Generic and biosimilar manufacturers should lock in pharmacy benefit manager formulary placements for denosumab biosimilars before the 2026 plan-year cycle closes. First-mover contracts secure preferred status, which determines share as Part B reimbursement and PBM rebates drive prescribing.

U.S. Osteoporosis Drugs: Market Overview

The U.S. osteoporosis drugs market is distinct because its economics are set by payers rather than patients. Roughly 10 million Americans have osteoporosis and more than 50 million have low bone mass, according to National Osteoporosis Foundation estimates. Total market value reached USD 4.6 billion in 2024, making the United States the largest single national market for these therapies worldwide. Growth is steady rather than explosive, which makes disciplined pricing strategy more important than volume expansion alone.

Compared with the global norm, the U.S. market leans heavily on Medicare: oral agents flow through Part D, while infused and injected drugs such as Prolia and Evenity are reimbursed under Part B. Generic alendronate and risedronate dominate oral volume, yet branded injectables carry most of the value. Roughly 300,000 hip fractures occur each year, and that clinical urgency sustains demand among women over 65. Few therapeutic categories in the country combine this volume with such exposure to federal pricing policy.

Growth Drivers in U.S. Osteoporosis Drugs

Demographic aging is the first driver. Roughly 60 million Americans were aged 65 and older in 2024, and Census Bureau projections show that figure surpassing 70 million by 2030 as the baby boom cohort completes its transition into later life. The U.S. Preventive Services Task Force recommends bone density screening for all women aged 65 and older, and Medicare Part B covers DXA testing for eligible beneficiaries, which expands the diagnosed pool that feeds treatment.

Second, anabolic therapies are gaining clinical traction, with the FDA approving romosozumab (Evenity, Amgen and UCB) in 2019 and abaloparatide (Tymlos, Radius Health) in 2017. Clinicians increasingly sequence these agents after denosumab, lifting revenue per treated patient. Third, the Inflation Reduction Act capped Part D out-of-pocket spending at USD 2,000 in 2025, which reduces abandonment of branded oral therapies among seniors.

Market Restraints and Entry Barriers

The clearest restraint is safety-driven. Prolia carries a boxed warning for severe hypocalcemia in patients with advanced chronic kidney disease, and both denosumab and bisphosphonates carry FDA labeling for atypical femoral fractures and osteonecrosis of the jaw. Discontinuing denosumab without a bridging agent causes rapid bone loss and vertebral fractures, which forces clinicians into costly sequential regimens and complicates prescribing for biosimilar switching.

Entry barriers are structural as well. Biologic entrants must file a 351(k) application under the Biologics Price Competition and Innovation Act of 2009, and interchangeability designation requires separate switching data. Pharmacy benefit managers extract rebates in exchange for preferred formulary status, while Part B's average sales price methodology means new entrants must win contracts before volume materializes. Patent thickets around denosumab delayed biosimilar entry until 2025.

Market Opportunities in the United States

Denosumab biosimilars create the most immediate opening in the medical benefit channel. With Sandoz, Celltrion and Samsung Bioepis entering the market, manufacturers able to supply private-label and interchangeable versions to large PBMs can capture share from Prolia. Analyst estimates place the addressable Part B denosumab spend at USD 1.8 billion by 2027, a pool that repricing will progressively open.

Fracture liaison services present a second route. Widely cited estimates indicate that roughly four in five patients who suffer a fragility fracture never receive osteoporosis treatment, a care gap that hospital-based programs and orthopedic networks can close. Entrants offering diagnostic partnerships, adherence support for injectables, and bone health monitoring tied to Medicare Annual Wellness Visits can secure prescribing relationships faster than traditional detailing allows.

Market at a Glance

MetricValue
Market Size 2024USD 4.6 billion
Market Size 2032USD 6.4 billion
Growth Rate (CAGR)4.2%
Most Critical Decision FactorMedicare Part B and Part D formulary access and net pricing
Largest RegionSouth Census Region
Competitive StructureConcentrated branded injectables; fragmented generic oral segment

Leading Market Participants

  • Amgen
  • UCB
  • Eli Lilly
  • Merck
  • Novartis
  • Sandoz
  • Celltrion
  • Samsung Bioepis
  • Radius Health
  • Teva Pharmaceuticals

Regulatory and Policy Environment

The regulatory framework rests on the Federal Food, Drug, and Cosmetic Act, the Biologics Price Competition and Innovation Act of 2009, and the Hatch-Waxman Act of 1984, all administered by the Food and Drug Administration. Medicare pricing is governed by the Inflation Reduction Act of 2022, which created the Medicare Drug Price Negotiation Program, and by Centers for Medicare and Medicaid Services payment rules that set Part B reimbursement at average sales price plus 6 percent, with ASP plus 8 percent for qualifying biosimilars through 2027.

Compliance timelines are tight. FDA biosimilar reviews carry a ten-month review goal under the Biosimilar User Fee Amendments, and interchangeability requires additional switching studies. Manufacturers must also comply with the federal Anti-Kickback Statute and Open Payments reporting, while the Federal Trade Commission monitors patent listings in the Orange Book. Negotiated Part D prices for the first ten selected drugs took effect on January 1, 2026, with subsequent selection cycles adding drugs in later years.

Long-Term Outlook for U.S. Osteoporosis Drugs

By 2032 the U.S. osteoporosis drugs market is forecast to reach USD 6.4 billion, growing at a CAGR of 4.2 percent from the 2025 base year. Value growth will come from anabolic agents and biosimilar injectables, while generic oral bisphosphonates will see volume grow as prices fall. The branded denosumab franchise will lose share as biosimilars enter Part B and PBM channels, and market leadership will consolidate around companies with both biologic manufacturing capacity and PBM contracting capabilities.

Investors should watch three variables through 2032: Centers for Medicare and Medicaid Services negotiation cycles, the pace of denosumab biosimilar uptake, and whether sequential anabolic regimens become guideline-standard. Companies that build fracture liaison partnerships and secure formulary placement early will protect volume as pricing tightens. The country's aging trajectory guarantees demand, but pricing policy will determine which entrants earn returns.

Frequently Asked Questions

Entrants file a 351(k) biologics license application with the FDA under the Biologics Price Competition and Innovation Act. Interchangeability designation requires switching data, and that step determines access to pharmacy-level substitution.
Part B pays average sales price plus 6 percent for most injectables. Qualifying biosimilars receive ASP plus 8 percent through 2027, which improves early-entry margins.
The Medicare Drug Price Negotiation Program sets negotiated prices for selected Part D drugs. The Part D out-of-pocket cap of USD 2,000 in 2025 also shapes net pricing and patient affordability.
Retail pharmacies handle most oral bisphosphonate volume, and pharmacy benefit managers control formulary access. Securing preferred status with the largest PBMs is therefore the decisive commercial step.
Under the Biosimilar User Fee Amendments, the FDA targets a ten-month review goal after filing acceptance. Manufacturers should plan for additional time if interchangeability studies are required.

Market Segmentation

By Drug Class
  • Bisphosphonates
  • RANKL Inhibitors
  • Anabolic Agents
  • Selective Estrogen Receptor Modulators
By Payer Type
  • Medicare Part B
  • Medicare Part D
  • Medicaid
  • Commercial Insurance
By Distribution Channel
  • Retail Pharmacies
  • Specialty Pharmacies
  • Hospital Pharmacies
  • Mail-Order Pharmacies

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Osteoporosis Drugs - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Drug Class Insights
4.1 Bisphosphonates
4.2 RANKL Inhibitors
4.3 Anabolic Agents
4.4 Selective Estrogen Receptor Modulators
4.5 Others
Chapter 05 Payer Type Insights
5.1 Medicare Part B
5.2 Medicare Part D
5.3 Medicaid
5.4 Commercial Insurance
5.5 Others
Chapter 06 Distribution Channel Insights
6.1 Retail Pharmacies
6.2 Specialty Pharmacies
6.3 Hospital Pharmacies
6.4 Mail-Order Pharmacies
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Amgen
7.2.2 UCB
7.2.3 Eli Lilly
7.2.4 Merck
7.2.5 Novartis
7.2.6 Sandoz
7.2.7 Celltrion
7.2.8 Samsung Bioepis
7.2.9 Radius Health
7.2.10 Teva Pharmaceuticals
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.